Syncona Ltd has officially submitted a 13F Notice, detailing its investment holdings as of September 30, 2026. This filing is significant as it provides insight into the company's investment strategies and the management of its assets.

Syncona Ltd, incorporated in Guernsey, operates in the biotechnology sector. The company is known for its focus on advancing life sciences through its various subsidiaries. Its recent filings include multiple 13F Notices and other regulatory submissions, indicating an active engagement with its investment portfolio.

The filing states, "The securities are owned directly by Syncona Portfolio Limited and indirectly by Syncona Portfolio Holdings LP, Syncona Holdings Limited, Syncona Limited, Christopher Hollowood and Kenneth Galbraith." This highlights the complex structure of ownership and management within the company, emphasizing the role of its investment committee in decision-making.

This filing may affect stakeholders in the biotech industry, particularly those looking to understand Syncona's investment strategies and how they align with broader market trends. The report also showcases the interconnectedness of its subsidiaries, which may influence how competitors view their own investment strategies.

The filing does not say what happens next.

Ownership Structure and Management

The filing provides a detailed overview of Syncona's complex ownership structure. Syncona Portfolio Limited is identified as a wholly owned subsidiary of Syncona Portfolio Holdings LP, which is a limited partnership. Syncona Holdings Limited serves as a limited partner in this partnership and is a wholly controlled subsidiary of Syncona Limited, the publicly-listed parent company. This intricate relationship underscores the strategic alignment and governance within the organization.

Investment and voting decisions regarding the securities are made by Syncona Portfolio Limited, which acts on the recommendations of the investment committee comprised of Christopher Hollowood and Kenneth Galbraith. This highlights the importance of the investment committee in guiding the company's investment strategies, ensuring that decisions are made with a focus on maximizing shareholder value.

Filing Details

The 13F Notice was filed with the SEC on November 5, 2026, and covers the period ending September 30, 2026. It is categorized under the 1934 Act and is assigned the SEC file number 028-21847. The filing indicates that Syncona Ltd is incorporated in Guernsey, with its fiscal year ending on March 31.

This filing does not include specific details about the types of securities held or their respective values, which are typically found in a complete 13F filing.